Journal
PHARMACOGENOMICS
Volume 16, Issue 6, Pages 573-582Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/PGS.15.23
Keywords
ADORA2A; dyskinesia; levodopa; Parkinson's disease
Categories
Funding
- Financiadora de Estudos e Projetos [FINEP 01.08.01230.00]
- 'Conselho Nacional de Desenvolvimento Cientifico e Tecnologico' (CNPq)
- Fundo de Incentivo a Pesquisa (FIPE - HCPA)
Ask authors/readers for more resources
Aim: Levodopa is first line treatment of Parkinson's disease (PD). However, its use is associated with the presence of motor fluctuations and dyskinesias. In recent years, adenosine A2A receptor (A2AR) is rising as a therapeutic target for PD. The aim of the present study was to investigate whether ADORA2A is associated with levodopa adverse effects. Patients & methods: Two hundred and eight PD patients on levodopa therapy were investigated. rs2298383 and rs3761422 at the ADORA2A gene were genotyped by allelic discrimination assays. Results: A trend for association was observed for both polymorphism and diplotypes with dyskinesia. Conclusion: The present results should be considered as positive preliminary evidence. Further studies are needed to determine the association between ADORA2A and dyskinesia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available